Virtu Financial LLC Acquires 39,681 Shares of Bellicum Pharmaceuticals Inc (BLCM)
Virtu Financial LLC raised its holdings in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 135.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 69,039 shares of the biopharmaceutical company’s stock after acquiring an additional 39,681 shares during the quarter. Virtu Financial LLC’s holdings in Bellicum Pharmaceuticals were worth $581,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after buying an additional 144,854 shares in the last quarter. State Street Corp lifted its position in Bellicum Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock valued at $4,872,000 after buying an additional 59,321 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Bellicum Pharmaceuticals during the third quarter valued at approximately $4,723,000. Northern Trust Corp lifted its position in Bellicum Pharmaceuticals by 29.5% during the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock valued at $3,989,000 after buying an additional 77,760 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Bellicum Pharmaceuticals by 223.5% during the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock valued at $1,612,000 after buying an additional 95,336 shares in the last quarter. 56.20% of the stock is currently owned by hedge funds and other institutional investors.
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) opened at $7.57 on Friday. Bellicum Pharmaceuticals Inc has a 12-month low of $5.02 and a 12-month high of $15.55. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08. The company has a market cap of $233.45, a price-to-earnings ratio of -2.53 and a beta of 0.44.
In other news, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.33, for a total transaction of $159,701.61. Following the transaction, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of Bellicum Pharmaceuticals stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total transaction of $2,248,978.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,158,939 shares of company stock worth $9,635,284. Corporate insiders own 18.77% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Virtu Financial LLC Acquires 39,681 Shares of Bellicum Pharmaceuticals Inc (BLCM)” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/03/03/virtu-financial-llc-acquires-39681-shares-of-bellicum-pharmaceuticals-inc-blcm.html.
Bellicum Pharmaceuticals Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals Inc (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.